Clearside Biomedical (NASDAQ:CLSD) Given Media Impact Rating of 0.11
Media stories about Clearside Biomedical (NASDAQ:CLSD) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Clearside Biomedical earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.0673719278251 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Clearside Expects to Report Top-Line Results in Q1-2018 (einpresswire.com)
- Clearside Biomedical (CLSD) Reports Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA (streetinsider.com)
- Cowen and Company Reaffirms “Buy” Rating for Clearside Biomedical, Inc. (CLSD) (americanbankingnews.com)
- Clearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious Uveitis (finance.yahoo.com)
Clearside Biomedical (NASDAQ:CLSD) opened at 8.00 on Tuesday. The firm’s market cap is $202.40 million. Clearside Biomedical has a 12 month low of $5.44 and a 12 month high of $25.08. The firm’s 50 day moving average is $9.15 and its 200-day moving average is $8.05.
Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings data on Wednesday, May 10th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.03. The company had revenue of $0.01 million during the quarter. Clearside Biomedical had a negative net margin of 154,030.02% and a negative return on equity of 53.20%. On average, equities analysts forecast that Clearside Biomedical will post ($1.72) EPS for the current year.
Several research analysts have weighed in on the stock. Cowen and Company reissued a “buy” rating on shares of Clearside Biomedical in a report on Monday. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Monday, April 10th. JMP Securities assumed coverage on shares of Clearside Biomedical in a research report on Thursday, May 25th. They set an “outperform” rating and a $21.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and set a $27.00 target price on shares of Clearside Biomedical in a research report on Thursday, April 20th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $19.00.
COPYRIGHT VIOLATION WARNING: “Clearside Biomedical (NASDAQ:CLSD) Given Media Impact Rating of 0.11” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/08/clearside-biomedical-nasdaqclsd-given-media-impact-rating-of-0-11.html.
In related news, insider Daniel H. White sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $7.89, for a total transaction of $63,120.00. Following the completion of the transaction, the insider now owns 504,067 shares of the company’s stock, valued at $3,977,088.63. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Daniel H. White sold 3,600 shares of the business’s stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $7.78, for a total transaction of $28,008.00. Following the transaction, the chief executive officer now directly owns 504,067 shares of the company’s stock, valued at approximately $3,921,641.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 125,170 shares of company stock valued at $1,080,884. 20.90% of the stock is owned by corporate insiders.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.